ReviewGastroenterology research and practice2016
Duodenal Rare Neuroendocrine Tumor: Clinicopathological Characteristics of Patients with Gangliocytic Paraganglioma.
Review in Gastroenterology research and practice, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Comparisons of the efficiency of respiratory rate monitoring devices and acoustic respiratory sound during endoscopic submucosal dissection.Journal of clinical monitoring and computing · 2022Trial
- Life-Threatening Gastrointestinal Bleeding Revealing a Rare Coexistence of Ampullary Ganglioneuroma and Pancreatic Neuroendocrine Tumor: A Case Report.Diagnostics (Basel, Switzerland) · 2026Article
- Endoscopic ultrasound-guided tissue acquisition using a novel Franseen needle for ampullary gangliocytic paraganglioma.Endoscopy · 2025Article
- Endoscopic Papillectomy for Ampullary Gangliocytic Paraganglioma: A Case Series and Literature Review.Internal medicine (Tokyo, Japan) · 2025Review
- Large Neuroendocrine Neoplasms of the Duodenum: Description of Two Rare Subtypes and Technical Details on Surgical Treatment.Diseases (Basel, Switzerland) · 2024Article
- Duodenal Gangliocytic Paragangliomas-Case Series and Literature Review.Life (Basel, Switzerland) · 2023Article
- Distinct cases of gangliocytic paraganglioma in the duodenum: Two case reports.Radiology case reports · 2022Article
- Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms.Endocrine pathology · 2022Review
- Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.Endocrine pathology · 2022Review
- Time to give up traditional methods for the management of gastrointestinal neuroendocrine tumours.World journal of clinical cases · 2021Review
- Gangliocytic Paraganglioma: A Rare Etiology of Obstructive Jaundice.The American journal of case reports · 2021Article
- Gangliocytic Paraganglioma of Ampulla Masquerading as a Neuroendocrine Tumor.Journal of gastrointestinal cancer · 2021Article
- Incidence, treatment, and survival analysis in esophageal neuroendocrine carcinoma population.Translational cancer research · 2020Article
- Extraluminal Duodenal Gangliocytic Paraganglioma Presenting with Intractable Back Pain in a Patient with End-Stage Renal Disease.Journal of gastrointestinal cancer · 2020Article
- Periampullary Gangliocytic Paraganglioma.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2019Article
- Gangliocytic paraganglioma: An overview and future perspective.World journal of clinical oncology · 2019Article
- Diagnosis, Pathological Findings, and Clinical Management of Gangliocytic Paraganglioma: A Systematic Review.Frontiers in oncology · 2018Article
- Risk factors associated with the progression and metastases of hindgut neuroendocrine tumors: a retrospective study.BMC cancer · 2017Article
- Diagnosis and Management of Upper Gastrointestinal Neuroendocrine Tumors.Clinical endoscopy · 2017Review
- Gangliocytic Paraganglioma: a Diagnostic Pitfall of Rare Neuroendocrine Tumor.Endocrine pathology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gangliocytic paraganglioma (GP) has been regarded as a rare benign tumor that commonly arises from the second part of the duodenum. As GP does not exhibit either prominent mitotic activity or Ki-67 immunoreactivity, it is often misdiagnosed as neuroendocrine tumor (NET) G1. However, the prognosis might be better in patients with GP than in those with NET G1. Therefore, it is important to differentiate GP from NET G1. Moreover, our previous study indicated that GP accounts for a substantial, constant percentage of duodenal NETs. In the present article, we describe up-to-date data on the clinicopathological characteristics of GP and on the immunohistochemical findings that can help differentiate GP from NET G1, as largely revealed in our new and larger literature survey and recent multi-institutional retrospective study. Furthermore, we would like to refer to differential diagnosis and clinical management of this tumor and provide intriguing information about the risk factors for lymph node metastasis on GP.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.